Literature DB >> 29503331

Deep brain stimulation for movement disorders.

Syam Krishnan1, Krishnakumar Kesava Pisharady1, K P Divya1, Kuldeep Shetty1, Asha Kishore1.   

Abstract

Deep Brain Stimulation (DBS) was introduced into clinical practice nearly four decades ago and is currently the standard of care for patients with Parkinson's disease experiencing motor complications. Apart from this, it has several other established and emerging applications in movement disorders. The exact mechanisms by which DBS provides relief in movement disorders are still unclear; disruption of pathological neuronal synchrony and abnormal information flow through the neuronal circuits involved, are the most likely underlying mechanisms. DBS has been established to be a relatively safe procedure if patients are carefully selected and followed up by experienced multidisciplinary teams. Alternatives to the traditional stereotactic frame based techniques of lead implantation are emerging, and these, along with the other recent technological advances, are likely to extend the availability of this therapy to an increasing number of patients in the future.

Entities:  

Keywords:  Deep Brain Stimulation; Parkinson's disease; dystonia; movement disorders

Mesh:

Year:  2018        PMID: 29503331     DOI: 10.4103/0028-3886.226438

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  2 in total

1.  Cognitive outcome following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease-a comparative observational study in Indian patients.

Authors:  Kshiteeja Jain; Remya Ramesh; Syam Krishnan; Krishnakumar Kesavapisharady; K P Divya; Sankara P Sarma; Asha Kishore
Journal:  Acta Neurol Belg       Date:  2021-08-26       Impact factor: 2.396

2.  Treating Post-traumatic Stress Disorder with Neuromodulation Therapies: Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation.

Authors:  Flavia Venetucci Gouveia; Benjamin Davidson; Ying Meng; Darryl Christopher Gidyk; Jennifer S Rabin; Enoch Ng; Agessandro Abrahao; Nir Lipsman; Peter Giacobbe; Clement Hamani
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.